The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Open accessAbstract
BACKGROUND: Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression. METHODS: In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score. RESULTS: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet velocity were 0.199+/-0.210 m per second per year in the atorvastatin group and 0.203+/-0.208 m per second per year in the placebo group (P=0.95; adjusted mean difference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year). Progression in valvular calcification was 22.3+/-21.0 percent per year in the atorvastatin group, and 21.7+/-19.8 percent per year in the placebo group (P=0.93; ratio of post-treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to 1.050). CONCLUSIONS: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression. This study cannot exclude a small reduction in the rate of disease progression or a significant reduction in major clinical end points. Long-term, large-scale, randomized, controlled trials are needed to establish the role of statin therapy in patients with calcific aortic stenosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several randomized trials showed no effect of statins on haemodynamic progression or AS-related clinical events152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three randomized clinical trials (RCTs) failed to demonstrate any significant benefit of LDL lowering with statins on the progression of AS152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Several intervention studies have been performed to test the hypothesis that lipid lowering with statin medications would slow the progression of AS, however the results were generally disappointing152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“randomized controlled trials (RCTs) failed to demonstrate any benefit of statin therapy on retard disease progression6–8.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Several clinical trials evaluating statin therapy in mild to moderate AS failed to demonstrate efficacy in lipid lowering as a strategy to mitigate adverse events in the disease39–41.”
From Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction (2026) · cites this paper as [39]
In the citing paper
“lipid-lowering therapy to delay progression of AS has been evaluated in 3 randomized controlled trials; however, all trials reported no significant benefit.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“The SALTIRE (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression) and ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trials, which evaluated statin efficacy in AS, were constrained by small sample sizes (n=150 and n=269), 12,13 limited median follow-up periods (25 and 42 months), and a focus on advanced AS stages (mean peak velocity, 3.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“All of the clinical trials aimed to halt the progression of established AS.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Second, we observed similar associations with AVR as a strict procedural outcome, which is particularly meaningful in the context of previous neutral clinical trials of lipid-lowering therapies that used AVR as the study end point.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12% per mmol/L reduction in LDL cholesterol), MI, and vascular death [459,460].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [459]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Suggestions for an association between aortic stenosis, LDL-C and Lp(a), as well as between cholesterol and increased risk for calcification of bioprosthetic valves, were matched with early observational noncontrolled trials that showed beneficial effects of aggressive lipid lowering in slowing the progression of aortic stenosis. However, this was not confirmed in RCTs. 243,377,378”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Zoghbi, W. A., Enriquez-Sarano, M. L., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quiñones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,041
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis
Rosenhek, R., Binder, T. M., Porenta, G., Lang, I. M., Christ, G., SCHEMPER, M., Maurer, G., & Baumgartner, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430903 · Cited by 1,332
Otto, C. M., Kuusisto, J., Reichenbach, D. D., Gown, A. M., & O’Brien, K. D. (1994) · Circulation · doi:10.1161/01.cir.90.2.844 · Cited by 1,315
Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly
Otto, C. M., Lind, B. K., Kitzman, D. W., Gersh, B. J., & Siscovick, D. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410302 · Cited by 1,281
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Guidelines on the management of valvular heart disease
Vahanian, A. S., Baumgartner, H., Bax, J. J., Butchart, E., Dion, R., Filippatos, G. S., Flachskampf, F., Hall, R., Iung, B., Kasprzak, J. D., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl428 · Cited by 3,579
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000031 · Cited by 2,920
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000029 · Cited by 2,566
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000932 · Cited by 2,449
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.007 · Cited by 2,245
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 2,110
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.021 · Cited by 1,702
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O'Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.537 · Cited by 1,642
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Assessment of Coronary Artery Disease by Cardiac Computed Tomography
Budoff, M. J., Achenbach, S. S., Blumenthal, R. S., Carr, J. J., Goldin, J. G., Greenland, P., Guerci, A. D., Lima, J. A. C., Rader, D. J., Rubin, G. D., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178458 · Cited by 1,400
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,364
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.190748 · Cited by 1,128
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.035 · Cited by 1,119
Demer, L. L., & Tintut, Y. (2008) · Circulation · doi:10.1161/circulationaha.107.743161 · Cited by 1,086
Siu, S. C., & Silversides, C. K. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.068 · Cited by 1,028
2014 AHA/ACC guideline for the management of patients with valvular heart disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.05.014 · Cited by 997
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
Johnson, R. C., Leopold, J. A., & Loscalzo, J. (2006) · Circulation Research · doi:10.1161/01.res.0000249379.55535.21 · Cited by 953
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842
Carabello, B. A., & Paulus, W. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60211-7 · Cited by 818
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Epidemiology of valvular heart disease in the adult
Iung, B., & Vahanian, A. S. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.202 · Cited by 743
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Aikawa, E. R., Nahrendorf, M., Figueiredo, J., Świrski, F. K., Shtatland, T., Köhler, R. H., Jaffer, F. A., Aikawa, M., & Weissleder, R. (2007) · Circulation · doi:10.1161/circulationaha.107.732867 · Cited by 694
Dweck, M. R., Boon, N. A., & Newby, D. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.093 · Cited by 692
Self-citationThe evolving epidemiology of valvular aortic stenosis. The Tromsø Study
Eveborn, G. W., Schirmer, H., Heggelund, G., Lunde, P., & Rasmussen, K. (2012) · Heart · doi:10.1136/heartjnl-2012-302265 · Cited by 660
Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis
Rennenberg, R. J. M. W., Kessels, Schurgers, L. J., Engelshoven, V. J. J., de Leeuw, P. W., & Kroon (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4822 · Cited by 471
Michelena, H. I., Prakash, S. K., Della Corte, A., Bissell, M. M., Anavekar, N., Mathieu, P., Bossé, Y., Limongelli, G., Bossone, E., Benson, D. W., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007851 · Cited by 442
Schoen, F. J. (2008) · Circulation · doi:10.1161/circulationaha.108.805911 · Cited by 421
Calcification in Aortic Stenosis
Pawade, T., Newby, D. E., & Dweck, M. R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.066 · Cited by 418
Self-citationRosuvastatin Affecting Aortic Valve Endothelium to Slow the Progression of Aortic Stenosis
Moura, L. M., Ramos, S., Zamorano, J. L., Barros, I. M., Azevedo, L. F., Rocha‐Gonçalves, F., & Rajamannan, N. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.072 · Cited by 402
Yutzey, K. E., Demer, L. L., Body, S. C., Huggins, G. S., Towler, D. A., Giachelli, C. M., Bowman, M. A. H., Mortlock, D. P., Rogers, M. B., Sadeghi, M. M., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.302523 · Cited by 386
Miller, J. D., Chu, Y., Brooks, R. M., Richenbacher, W. E., Peña-Silva, R., & Heistad, D. D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.043 · Cited by 357
Zheng, K. H., Tsimikas, S., Pawade, T., Kroon, J., Jenkins, W. S. A., Doris, M. K., White, A. C., Timmers, N. K. L. M., Hjortnaes, J., Rogers, M. A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.070 · Cited by 353
Self-citationMolecular Mechanisms of Vascular Calcification
Shao, J.-S., Cai, J., & Towler, D. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000220441.42041.20 · Cited by 348
Goody, P. R., Hosen, M. R., Christmann, D., Niepmann, S. T., Zietzer, A., Adam, M., Bönner, F., Zimmer, S., Nickenig, G., & Jansen, F. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313067 · Cited by 358
Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Dweck, M. R., Jones, C., Joshi, N. V., Fletcher, A. M., Richardson, H., White, A., Marsden, M., Pessotto, R., Clark, J. C., Wallace, W. A., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.051052 · Cited by 337
Self-citationThe modern epidemiology of heart valve disease
Coffey, S., Cairns, B. J., & Iung, B. (2015) · Heart · doi:10.1136/heartjnl-2014-307020 · Cited by 326
Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms
Miller, J. D., Weiss, R. M., & Heistad, D. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.234138 · Cited by 332
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Qunibi, W. Y., Moustafa, M., Muenz, L. R., He, D. Y., Kessler, P., Díaz-Buxó, J. A., & Budoff, M. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.298 · Cited by 305
Matrix Gla-protein: The calcification inhibitor in need of vitamin K
Cranenburg, E. C. M., Vermeer, C., & Schurgers, L. J. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-02-0087 · Cited by 304
Allison, M., Cheung, P., Criqui, M. H., Langer, R. D., & Criqui, M. H. (2006) · Circulation · doi:10.1161/circulationaha.105.552844 · Cited by 301
Généreux, P., Stone, G. W., O’Gara, P. T., Marquis‐Gravel, G., Redfors, B., Giustino, G., Pîbarot, P., Bax, J. J., Bonow, R. O., & Leon, M. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.057 · Cited by 299
Pathogenesis of Calcific Aortic Valve Disease
O’Brien, K. D. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000227513.13697.ac · Cited by 298
Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats
Schurgers, L. J., Spronk, H. M. H., Soute, B. A. M., Schiffers, P. M. H., DeMey, J. G. R., & Vermeer, C. (2006) · Blood · doi:10.1182/blood-2006-07-035345 · Cited by 288
Acute Rheumatic Fever and Rheumatic Heart Disease
Lawrence, J. G., Carapetis, J. R., Griffiths, K. E., Edwards, K. N., & Condon, J. R. (2013) · Circulation · doi:10.1161/circulationaha.113.001477 · Cited by 283
Katz, R., Wong, N. D., Kronmal, R. A., Takasu, J., Shavelle, D. M., Probstfield, J. L., Bertoni, A. G., Budoff, M. J., & O’Brien, K. D. (2006) · Circulation · doi:10.1161/circulationaha.105.598086 · Cited by 282
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
The Global Burden of Aortic Stenosis
Thaden, J. J., Nkomo, V. T., & Enriquez-Sarano, M. L. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.02.006 · Cited by 277
2020 ACC/AHA guideline for the management of patients with valvular heart disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.002 · Cited by 279
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Serotonin receptors and heart valve disease—It was meant 2B
Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.008 · Cited by 256
The Prevalence, Incidence, Progression, and Risks of Aortic Valve Sclerosis
Coffey, S., Cox, B., & Williams, M. J. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.018 · Cited by 255
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Cellular Mechanisms of Aortic Valve Calcification
Leopold, J. A. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.112.971028 · Cited by 264
Association Between Cardiovascular Risk Factors and Aortic Stenosis
Yan, A. T., Koh, M., Chan, K. K., Guo, H., Alter, D. A., Austin, P. C., Tu, J. V., Wijeysundera, H. C., & Ko, D. T. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.025 · Cited by 247
Left Ventricular Outflow Obstruction
Aboulhosn, J., & CHILD, J. S. (2006) · Circulation · doi:10.1161/circulationaha.105.592089 · Cited by 245
Smith, J. G., Luk, K., Schulz, C.-A., Engert, J. C., Do, R., Hindy, G., Rukh, G., Dufresne, L., Almgren, P., Owens, D. S., et al. (2014) · JAMA · doi:10.1001/jama.2014.13959 · Cited by 238
Chin, C. W. L., Shah, A. S. V., McAllister, D. A., Joanna Cowell, S., Alam, S., Langrish, J. P., Strachan, F. E., Hunter, A. L., Maria Choy, A., Lang, C. C., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu189 · Cited by 233
Self-citationInsights Into Degenerative Aortic Valve Disease
Goldbarg, S. H., Elmariah, S., Miller, M. A., & Fuster, V. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.024 · Cited by 239
Nakano-Kurimoto, R., Ikeda, K., Uraoka, M., Nakagawa, Y., Yutaka, K., Koide, M., Takahashi, T., Matoba, S., Yamada, H., Okigaki, M., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00455.2009 · Cited by 230
Liberman, M., Bassi, E., Martinatti, M. K., Lario, F. C., Wosniak, J., Pomerantzeff, P. M. A., & Laurindo, F. R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.156745 · Cited by 225
Calcific Aortic Valve Stenosis in Old Hypercholesterolemic Mice
Weiss, R. M., Ohashi, M., Miller, J. D., Young, S. G., & Heistad, D. D. (2006) · Circulation · doi:10.1161/circulationaha.106.634139 · Cited by 222
Role of Human Valve Interstitial Cells in Valve Calcification and Their Response to Atorvastatin
Osman, L., Yacoub, M. H., Latif, N., Amrani, M., & Chester, A. H. (2006) · Circulation · doi:10.1161/circulationaha.105.001115 · Cited by 219
Inflammation Is Associated with the Remodeling of Calcific Aortic Valve Disease
Coté, N., Mahmut, A., Bosse, Y., Couture, C., Pagé, S., Trahan, S., Boulanger, M.-C., Fournier, D., Pibarot, P., & Mathieu, P. (2013) · Inflammation · doi:10.1007/s10753-012-9579-6 · Cited by 218
Aortic valve disease and treatment: The need for naturally engineered solutions
Butcher, J. T., Mahler, G. J., & Hockaday, L. A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.008 · Cited by 220
Messika–Zeitoun, D., Bielak, L. F., Peyser, P. A., Sheedy, P. F., Turner, S. T., Nkomo, V. T., Breen, J. F., Maalouf, J. F., Scott, C. G., Tajik, A. J., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255952.47980.c2 · Cited by 206
Son, B., Kozaki, K., Iijima, K., Eto, M., Kojima, T., Ota, H., Senda, Y., Maemura, K., Nakano, T., Akishita, M., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000218859.90970.8d · Cited by 205
Hakuno, D., Kimura, N., Yoshioka, M., Mukai, M., Kimura, T., Okada, Y., Yozu, R., Shukunami, C., Hiraki, Y., Kudō, A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40973 · Cited by 207
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.030 · Cited by 198
The mechanism of vascular calcification – a systematic review
Karwowski, W., Naumnik, B., Szczepański, M., & Myśliwiec, M. (2012) · Medical Science Monitor · doi:10.12659/msm.882181 · Cited by 201
Houslay, E. S., Cowell, S. J., Prescott, R. J., Reid, J. H., Burton, J., Northridge, D. B., Boon, N. A., & Newby, D. E. (2006) · Heart · doi:10.1136/hrt.2005.080929 · Cited by 182
Self-citationMohty, D., Pibarot, P., Després, J.-P., Côté, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C., & Mathieu, P. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.154989 · Cited by 181
Management of Patients With Aortic Valve Stenosis
Kanwar, A., Thaden, J. J., & Nkomo, V. T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.01.020 · Cited by 182
Calcific aortic stenosis: an update
Rajamannan, N. M., Bonow, R. O., & Rahimtoola, S. H. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0827 · Cited by 176
Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis
Briand, M., Lemieux, I., Dumesnil, J. G., Mathieu, P., Cartier, A., Després, J., Arsenault, M., Couët, J., & Pîbarot, P. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.073 · Cited by 168
Medical Treatment of Aortic Stenosis
Marquis‐Gravel, G., Redfors, B., Leon, M. B., & Généreux, P. (2016) · Circulation · doi:10.1161/circulationaha.116.023997 · Cited by 179
Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study
Nazarzadeh, M., Pinho-Gomes, A.-C., Bidel, Z., Dehghan, A., Canoy, D., Hassaine, A., Ayala Solares, J. R., Salimi-Khorshidi, G., Smith, G. D., Otto, C. M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa070 · Cited by 163
Role of p38 MAPK in Atherosclerosis and Aortic Valve Sclerosis
Reustle, A., & Torzewski, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123761 · Cited by 162
Ix, J. H., Chertow, G. M., Shlipak, M. G., Brandenburg, V. M., Ketteler, M., & Whooley, M. A. (2007) · Circulation · doi:10.1161/circulationaha.106.682450 · Cited by 160
Side-Specific Endothelial-Dependent Regulation of Aortic Valve Calcification
Richards, J. M. J., El-Hamamsy, I., Chen, S., Sarang, Z., Sarathchandra, P., Yacoub, M. H., Chester, A. H., & Butcher, J. T. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.037 · Cited by 168
Introduction to Aortic Stenosis
Carabello, B. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.300156 · Cited by 164
Novel Aspects of Oxidative Stress in Cardiovascular Diseases
Heistad, D. D., Wakisaka, Y., Miller, J. D., Chu, Y., & Silva, R. A. P. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1082 · Cited by 158
Pawade, T., Doris, M. K., Bing, R., White, A. C., Forsyth, L., Evans, E., Graham, C., Williams, M. C., van Beek, E. J. R., Fletcher, A. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053708 · Cited by 165
Self-citationLarge animal models of cardiovascular disease
Tsang, H. G., Rashdan, N. A., Whitelaw, C. B. A., Corcoran, B. M., Summers, K. M., & MacRae, V. E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3173 · Cited by 154
Wenaweser, P., Stortecky, S., Schwander, S., Heg, D., Huber, C. H., Pilgrim, T., Gloekler, S., O'Sullivan, C. J., Meier, B., Jüni, P., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht086 · Cited by 153
Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice
Miller, J. D., Weiss, R. M., Serrano, K. M., Brooks, R. M., Berry, C. J., Zimmerman, K., Young, S. G., & Heistad, D. D. (2009) · Circulation · doi:10.1161/circulationaha.108.834614 · Cited by 153
Dweck, M. R., Khaw, H., Sng, G., Luo, E., Baird, A., Williams, M. C., Makiello, P., Mirsadraee, S., Joshi, N. V., van Beek, E. J. R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht034 · Cited by 152
Self-citationMarwick, T. H., Amann, K., Bangalore, S., Cavalcante, J. L., Charytan, D. M., Craig, J. C., Gill, J. S., Hlatky, M. A., Jardine, A. G., Landmesser, U., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.06.025 · Cited by 149
Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study
Rossebø, A. B., Pedersen, T. R., Allen, C., Boman, K., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, V. A. Y., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.064 · Cited by 147
Molecular and cellular mechanisms of aortic stenosis
Yetkın, E., & Waltenberger, J. L. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.108 · Cited by 146
Metadata
- Authors
- Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A.
- Affiliations
- Edinburgh Royal Infirmary (GB)
- University of Edinburgh (GB)
- Borders General Hospital (GB)
- Western General Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-09
- Volume
- 352
- Issue
- 23
- Pages
- 2389-2397
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117330772
- Cited by
- 1,146
- References
- 41
- Citations by year
- 2026: 46 · 2025: 52 · 2024: 57 · 2023: 37 · 2022: 47 · 2021: 44 · 2020: 59 · 2019: 38 · 2018: 39 · 2017: 52 · 2016: 52 · 2015: 37 · 2014: 65 · 2013: 64 · 2012: 55
- FWCI
- 47.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- calcific aortic stenosis, atorvastatin, statin therapy, lipid-lowering therapy, valve calcification, disease progression, aortic jet velocity, aortic valve calcium score, LDL cholesterol, hypercholesterolemia, atherosclerosis, echocardiography, CT angiography
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, Aortic Valve, Aortic Valve Stenosis, Blood Flow Velocity, Calcinosis, Double-Blind Method, Heptanoic Acids, Humans, Cholesterol, LDL, Pyrroles, Echocardiography, Doppler, Treatment Failure, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
